...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
...aboratory and a worldwide leader in innovative lab...xtensive test menu of highly complex and unique me...ned by the University of Utah, ARUP Laboratories' ...versity teaching hospitals and children's hospital...
Medicine Products:(Date:9/5/2008)...e/ -- As the general election,campaign begins in e...nt,Business ( http://www.nfib.com ) is looking to ...s on the healthcare concerns of small,business. No...re over, NFIB,is asking both candidates to fully c...usinesses as they further develop their healthcare...
(Date:9/5/2008)...disease resistance to anti-hormonal therapy , ...ug sorafenib may help "re-sensitize" certain breas...n University Medical Center researchers say. , ...tor positive (ER or PR positive) metastatic breast...as aromatase inhibitors, to keep the cancer under ...
(Date:9/5/2008)...ositive, metastatic breast cancer may take medicat...ut when the tumor becomes resistant to anti-hormon...only option. But a study presented today at the 20...roach. Early data suggests a new treatment approa...monal drugs to do their job once again. , The st...
(Date:9/5/2008)...ek,s Annual Destination to Feature VelaShape. , ... September 5, 2008 -- http://www.americanlaser.co...r], the largest provider of laser hair removal and... announces sponsorship of the STYLE360 show during..., serves as the alternative Fashion Week destinati...
Breaking Medicine News(10 mins):Health News:Conventions Conclude, Fall Campaign Begins: NFIB Looks for More Focus on Small Business Healthcare Concerns 2Health News:Conventions Conclude, Fall Campaign Begins: NFIB Looks for More Focus on Small Business Healthcare Concerns 3Health News:Drug Re-Sensitizes Breast Tumors to Treatment 2Health News:1 step back ... 2 steps forward 2Health News:American Laser Centers Sponsors STYLE360 to Share the Skinny on Body Shaping 2(Date:9/5/2008)...Extracted From a Simple Blood Draw Have,the Potent...a Wide Range of Indic...Genomics is Currently Developing a B...Israel and JERSEY CITY, New Jersey, September 5,/P...SDQ: ROSG), a leader in,the development of microRN...
(Date:9/4/2008)...eal-time PCR testing for the diagnostic ...ept. 4 /- The U.S. Food & Drug,Admini...Man(R) HBV Test,the first assay for quantitating ...t uses Roche,s real-time PCR technology to quantif...,s blood. Doctors may use viral load,testing resul...
(Date:9/4/2008)...Women at More Than 100 Sites in the U.S., ANN ARB...uticals, a,privately-held biopharmaceutical compan...compounds to treat endocrine, metabolic and,cardio...itiated a second,Phase 3 clinical trial of Ophena(...ree oral therapy in development for the treatment ...
(Date:9/4/2008)...tification for Targeted Therapies Tha...TINGTON BEACH, Calif., and AMSTERDAM, Netherlands,...n molecular cancer diagnostics,today announced th...that,allows physicians to quantitatively determine...or (ER), progesterone receptor (PR) and Human Epid...
Breaking Medicine Technology:Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 2Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 3Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum 4FDA Approves First Hepatitis B Viral Load Test 2FDA Approves First Hepatitis B Viral Load Test 3QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 2QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome 3Agendia Launches TargetPrint(R) for Breast Cancer Patients 2Crystal 28eye 29 ball 3A Study says visual system equipped with future seeing powers 3326 1Crystal 28eye 29 ball 3A Study says visual system equipped with future seeing powers 3326 2Crystal 28eye 29 ball 3A Study says visual system equipped with future seeing powers 3326 3Sharps Compliance Corp Announces Results for Third Quarter of Fiscal Year 2008 19473 1Sharps Compliance Corp Announces Results for Third Quarter of Fiscal Year 2008 19473 2Sharps Compliance Corp Announces Results for Third Quarter of Fiscal Year 2008 19473 3Sharps Compliance Corp Announces Results for Third Quarter of Fiscal Year 2008 19473 4Sharps Compliance Corp Announces Results for Third Quarter of Fiscal Year 2008 19473 5Sharps Compliance Corp Announces Results for Third Quarter of Fiscal Year 2008 19473 6Sharps Compliance Corp Announces Results for Third Quarter of Fiscal Year 2008 19473 7Sharps Compliance Corp Announces Results for Third Quarter of Fiscal Year 2008 19473 8Sharps Compliance Corp Announces Results for Third Quarter of Fiscal Year 2008 19473 9Sharps Compliance Corp Announces Results for Third Quarter of Fiscal Year 2008 19473 10Sharps Compliance Corp Announces Results for Third Quarter of Fiscal Year 2008 19473 11Sharps Compliance Corp Announces Results for Third Quarter of Fiscal Year 2008 19473 12Sharps Compliance Corp Announces Results for Third Quarter of Fiscal Year 2008 19473 13Somanetics Corporation to Present at Citigroup 2008 Healthcare Conference 19468 1Somanetics Corporation to Present at Citigroup 2008 Healthcare Conference 19468 2Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2079 1Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2079 2...ech (ACTI.ST), today,announced new positive clinic...reatment of prostate cancer. , By step-wise dose e...ieved, which corresponds to a doubling of the prev... of 0.5 mg/day. This,means that a step-wise intra-... to be administered in future clinical trials. , "...
...eragenix Pharmaceuticals,Inc. (OTCBB:CGXP), a bio...se and dermatology, today announced that a cathete...irtually no biofilm,formation in a 21 day study., ...Ceragenins,were soaked daily in a phosphate-suffer...ay 21, the catheters were challenged with,an inocu...
Other Medicine Technology:Positive Clinical Data for TASQ - Active Biotech's Novel Treatment,of Prostate Cancer 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 3